Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Pfizer Biopharma Revenues Excluding Comirnaty & Paxlovid by Year
Pfizer Biopharma Revenues Excluding Comirnaty & Paxlovid ($M) ($M)
Pfizer Pfizer Biopharma Revenues Excluding Comirnaty & Paxlovid: $54,470M in FY2025, up 6.1% from a year earlier.
Latest, FY2025
54,470
Period ended Dec 31, 2025
Change on a year earlier
+6.1%
51,331 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-K Note 17 Segment & Geographic Information.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Pfizer Biopharma Revenues Excluding Comirnaty & Paxlovid ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 54,470 | +6.1% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 51,331 | +12.2% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 45,738 | +6.2% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 43,084 | – | Form 10-K (filed 2025-02-27) ↗ |
Cite this data
StockData. (2026). Pfizer Pfizer Biopharma Revenues Excluding Comirnaty & Paxlovid ($M), annual FY2022–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/rev-biopharma-ex-covid
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.